Brief: Everest Medicines Announces Approval Of Investigational New Drug Application By China NMPA For SPR206
24/09/2021 05:08
Sept 24 (Reuters) - Everest Medicines Ltd 1952.HK :
* ANNOUNCES APPROVAL OF INVESTIGATIONAL NEW DRUG APPLICATION
BY
CHINA NMPA FOR SPR206
Source text for Eikon: ID:
Further company coverage: 1952.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Everest Medicines
See all newsBrief: Everest Medicines Says NMPA Approves Cardamyst (Etripamil) NDA For PSVT In Adults In China
Brief: Everest Medicines Enters Commercialization Collaboration With Hainan Herui Pharmaceutical
Brief: Everest Medicines Says CBC Group Purchases 712,000 Everest Medicines Shares For Hk$19.2 Million From 16 To 17 June
Australia's Dimerix soars on commercialisation deal with Everest Medicines
Brief: Dimerix Ltd Licenses Dmx200 To Everest For China And Asia Region